CiVentiChem expands into phase 1 drug development services

Published: 4-Feb-2008

North Carolina-based contract research organisation CiVentiChem is building a new pilot plant with cGMP capabilities in India, expanding its offering of medicinal chemistry and custom synthesis services.


North Carolina-based contract research organisation CiVentiChem is building a new pilot plant with cGMP capabilities in India, expanding its offering of medicinal chemistry and custom synthesis services.

Headquartered near the Research Triangle Park in Cary, the company's new pilot plant will be built on the site of its Indian subsidiary Indus Biosciences in Hyderabad. All the work carried out at Indus Biosciences will be managed from its global headquarters in Cary, however, to ensure careful protection of IP.

Indus Biosciences currently occupies a 12,000 sq ft building with a staff of 50 chemists. It has the capability to carry out multi-step organic synthesis, chiral chemistry and process optimisation. The new 50,000 sq ft pilot plant, which represents a $7-8m investment, will have equipment ranging from 200- 2500 litre vessels, hydrogenation equipment, high potency labs, cGMP suites and in-process QC capabilities.

With this addition, the company will be able to increase its flexibility in providing clients with gram to multi-ton scale products.

You may also like